FDA Approves "Unprecedented" Risk Management Program For Accutane
This article was originally published in The Pink Sheet Daily
Executive Summary
Wholesalers, pharmacists, prescribers and patients will have added responsibility under the iPLEDGE program.
You may also be interested in...
US FDA Asks Manufacturers To Fix Disruption In Isotretinoin REMS
The agency offers ‘regulatory flexibility’ for certain requirements of the iPLEDGE REMS for the acne drug if manufacturers address delays in implementing the modified program.
REMS Refinement: Does iPLEDGE’s Evolution Have Lessons For Opioids?
The Drug Safety and Risk Management and Dermatologic and Ophthalmic Drugs Advisory Committees will assess the risk management program Dec. 1 for lessons about implementing REMS containing elements to assure safe use and selecting assessment metrics.
Accutane iPLEDGE Debut On Track Despite Calls For Delay
FDA confirmed that it would not delay the March 1 implementation of the isotretinoin risk management program.